Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 9.2% in the afternoon session after Bloomberg reported that Visa enrolled the telehealth company in its Acquirer Monitoring Program following a surge in customer credit card disputes in its weight-loss subscription business.

LOS ANGELES, Aug. 24, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz continues its investigation of Hims &

Visa placed Hims & Hers Health into its Acquirer Monitoring Program after a billing dispute spike, adding penalty costs amid an FTC lawsuit and margin contraction.

In a challenge brought by Kenvue Inc., BBB National Programs’ National Advertising Division determined that Hims & Hers Health, Inc. provided a reasonable basis for its comparative efficacy claim. However, the National Advertising Division (NAD) recommended that it modify or discontinue other claims regarding doctor-trusted ingredients, dermatologist recommendations, safety and side effects.

Law firm Kaplan Fox & Kilsheimer LLP has announced an investigation into potential securities law violations by Hims & Hers Health, Inc. (NYSE: HIMS) following a lawsuit filed by the Federal Trade Commission and state authorities on July 29, 2026. The legal action alleges the telehealth company engaged in deceptive billing, subscription cancellation obstruction, and improper sharing of consumers' health data with third parties. Shares of Hims & Hers fell $4.32 per share, or 14.73%, closing at $25.00 on the day the lawsuit was announced, a development investors may be closely monitoring.

FTC, California, and Utah sued Hims & Hers over misleading subscription practices and unauthorized sharing of sensitive health data.

Hims & Hers Health (HIMS) stock is back in focus after the Federal Trade Commission and state regulators filed a civil enforcement action, followed by a consumer class action targeting the company’s telehealth privacy and subscription practices. See our latest analysis for Hims & Hers Health. The latest 1-day share price return of 6.03% and 7-day return of 20.00% put Hims & Hers Health back in sharp focus. However, the 1-year total shareholder return is down 24.21%, while the 3-year total...

Hims & Hers Health (HIMS) Shares Drop 14.73% After FTC Files Lawsuit; Kaplan Fox Launches Securities Probe

Kaplan Fox & Kilsheimer LLP ha anunciado que está investigando posibles violaciones de la ley de valores por parte de Hims & Hers Health, Inc. (NYSE: HIMS) luego de una demanda presentada por la Comisión Federal de Comercio y las autoridades estatales el 29 de julio de 2026. La acción de la FTC alega prácticas de facturación no divulgadas, obstáculos a la cancelación de suscripciones y el intercambio inadecuado de datos de salud del consumidor con terceros, incluidos Meta y Snap. Las acciones de Hims & Hers cayeron 4,32 dólares, o un 14,73%, para cerrar en 25,00 dólares el día en que se anunció la demanda, un hecho que los inversores tal vez estén siguiendo de cerca.